Literature DB >> 32865702

The use of Modified Rio score for determining treatment failure in patients with multiple sclerosis: retrospective descriptive case series study.

Mesude Tutuncu1, Ayse Altintas2, Burcu V Dogan3, Ugur Uygunoglu4, Nilufer Kale Icen5, Ayse Deniz Elmalı6, Eda Coban3, Bengi G Alpaslan4, Aysun Soysal3,7.   

Abstract

Predicting treatment failure and switching effective treatment immediately in patients with multiple sclerosis (MS) is important. We aimed to evaluate the usefulness of Modified Rio score (MRS) in predicting treatment failure in MS patients. This is a retrospective study, which was conducted in two University Hospital. 129 MS patients treated with İnterferon or glatiramer-acetate from 2 clinical sites, were retrospectively selected. MRS was calculated after the first year of therapy. Treatment failure was defined as the presence of a 1 point increase in EDSS, 2 clinical attacks, 1 clinical attack and progression, 1 clinical attack and new lesion on MRI except associated with an attack, or new lesion in 2 different MRI taken at least 3 months apart. The sensitivity, specificity, positive and negative predictive values of the MRS in predicting treatment failure were determined. 71 (55%) patients with score '0', 41 (31.8%) patients with score '1', 11 (8.5%) patients with score '2', 6 (4.7%) patients with score '3' were detected. 14 patients needed treatment switching during the first three years of the treatment. Sensitivity was 57%, specificity was 92%, positive predictive value was 95%, negative predictive value was 47% and accuracy was 89%. Modified Rio score (MRS) was found to be effective in determining the treatment failure as mentioned before. This study will be useful for clinicians who evaluate the treatment failure like us, and this study revealed that the MRS may also help predict treatment failure.
© 2020. Belgian Neurological Society.

Entities:  

Keywords:  Disability; Multiple sclerosis; Treatment response

Mesh:

Substances:

Year:  2020        PMID: 32865702     DOI: 10.1007/s13760-020-01476-2

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN: 0300-9009            Impact factor:   2.396


  11 in total

Review 1.  MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials.

Authors:  Maria Pia Sormani; Paolo Bruzzi
Journal:  Lancet Neurol       Date:  2013-06-03       Impact factor: 44.182

2.  Validation of 1-year predictive score of long-term response to interferon-β in everyday clinical practice multiple sclerosis patients.

Authors:  M Romeo; V Martinelli; M Rodegher; E Perego; S Maida; M P Sormani; G Comi
Journal:  Eur J Neurol       Date:  2015-04-06       Impact factor: 6.089

Review 3.  Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge.

Authors:  Claudio Gasperini; Luca Prosperini; Mar Tintoré; Maria Pia Sormani; Massimo Filippi; Jordi Rio; Jacqueline Palace; Maria A Rocca; Olga Ciccarelli; Frederik Barkhof; Jaume Sastre-Garriga; Hugo Vrenken; Jette L Frederiksen; Tarek A Yousry; Christian Enzinger; Alex Rovira; Ludwig Kappos; Carlo Pozzilli; Xavier Montalban; Nicola De Stefano
Journal:  Neurology       Date:  2018-12-26       Impact factor: 9.910

Review 4.  Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis.

Authors:  Dalia Rotstein; Xavier Montalban
Journal:  Nat Rev Neurol       Date:  2019-05       Impact factor: 42.937

5.  Assessing response to interferon-β in a multicenter dataset of patients with MS.

Authors:  Maria Pia Sormani; Claudio Gasperini; Marzia Romeo; Jordi Rio; Massimiliano Calabrese; Eleonora Cocco; Christian Enzingher; Franz Fazekas; Massimo Filippi; Antonio Gallo; Ludwig Kappos; Maria Giovanna Marrosu; Vittorio Martinelli; Luca Prosperini; Maria Assunta Rocca; Alex Rovira; Till Sprenger; Maria Laura Stromillo; Gioacchino Tedeschi; Mar Tintorè; Carla Tortorella; Maria Trojano; Xavier Montalban; Carlo Pozzilli; Giancarlo Comi; Nicola De Stefano
Journal:  Neurology       Date:  2016-06-15       Impact factor: 9.910

6.  Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.

Authors:  G Comi; P O'Connor; X Montalban; J Antel; E-W Radue; G Karlsson; H Pohlmann; S Aradhye; L Kappos
Journal:  Mult Scler       Date:  2009-12-22       Impact factor: 6.312

7.  Multiple sclerosis in the Republic of San Marino, Italian peninsula: an incidence and prevalence study from a high-risk area.

Authors:  Marta Caniglia-Tenaglia; Susanna Guttmann; Chiara Monaldini; Dario Manzaroli; Mirco Volpini; Maurizio Stumpo; Elisabetta Groppo; Ilaria Casetta; Vittorio Govoni; Mattia Fonderico; Maura Pugliatti; Enrico Granieri
Journal:  Neurol Sci       Date:  2018-04-18       Impact factor: 3.307

8.  Relapses and progression of disability in multiple sclerosis.

Authors:  C Confavreux; S Vukusic; T Moreau; P Adeleine
Journal:  N Engl J Med       Date:  2000-11-16       Impact factor: 91.245

9.  Long-term disability outcomes in relapsing-remitting multiple sclerosis: a 10-year follow-up study.

Authors:  Jelena Drulovic; Jovana Ivanovic; Sarlota Mesaros; Vanja Martinovic; Darija Kisic-Tepavcevic; Irena Dujmovic; Tatjana Pekmezovic
Journal:  Neurol Sci       Date:  2019-04-22       Impact factor: 3.307

10.  Disability progression in multiple sclerosis: a Tunisian prospective cohort study.

Authors:  Emna Hentati; Samia Ben Sassi; Fatma Nabli; Tarek Mabrouk; Mourad Zouari; Fayçal Hentati
Journal:  Neurol Sci       Date:  2018-02-23       Impact factor: 3.307

View more
  3 in total

1.  Predicting Long-term Disability in Multiple Sclerosis: A Narrative Review of Current Evidence and Future Directions.

Authors:  Bianca Weinstock-Guttman; Maria Pia Sormani; Pavle Repovic
Journal:  Int J MS Care       Date:  2022-10-05

2.  Evaluation of the expressed miR-129 and miR-549a in patients with multiple sclerosis.

Authors:  Mina Montazeri; Nahid Eskandari; Reza Mansouri
Journal:  Adv Biomed Res       Date:  2021-12-25

Review 3.  Predictive MRI Biomarkers in MS-A Critical Review.

Authors:  Vlad Eugen Tiu; Iulian Enache; Cristina Aura Panea; Cristina Tiu; Bogdan Ovidiu Popescu
Journal:  Medicina (Kaunas)       Date:  2022-03-03       Impact factor: 2.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.